We aimed to establish which low doses of IL2 would be safe and induce Treg cells in patients with type 1 diabetes , considering that : ( 1 ) type 1 diabetes might be linked to alteration of the IL2/IL2R activation pathway ; ( 2 ) activation of pathogenic Teff cells by IL2 could exacerbate disease ; and ( 3 ) the safety of low-dose IL2 is not known in type 1 diabetes .